SciSparc Advances with Clinical Trial Application
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company focused on innovative treatments, has made an important move in addressing Tourette Syndrome. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration. This application is essential for launching a Phase IIb clinical trial that will evaluate the effectiveness of their unique drug candidate, SCI-110.
Trial Locations and Oversight
The upcoming clinical trial will be hosted at three esteemed research centers: the Yale Child Study Center at Yale School of Medicine in the United States, Hannover Medical School in Germany, and Tel Aviv Sourasky Medical Center in Israel. Approval processes are already complete, with all necessary Institutional Review Board (IRB) permissions secured. Moreover, the company has obtained the required regulatory clearances from health authorities in both Israel and Germany, allowing them to initiate the trial without any hold-ups.
Goals of the Clinical Trial
The main focus during the Phase IIb trial will be to evaluate the safety, efficacy, and tolerability of SCI-110 in adults aged 18 to 65 with Tourette Syndrome. Participants will be randomly assigned to receive either the drug or a placebo in a structured method designed to yield reliable results. The effectiveness of SCI-110 will be assessed using the Yale Global Tic Severity Scale, a widely recognized tool in clinical settings for measuring tic severity.
Impact on Patient Care
This study intends to provide valuable insights into the drug’s effectiveness while also closely monitoring safety, including tracking any serious adverse events among participants. Given the difficulties posed by Tourette Syndrome, which can significantly disrupt daily life, a successful trial could lead to revolutionary results and create better treatment alternatives for those affected.
About SciSparc Ltd.
SciSparc Ltd. is dedicated to developing innovative therapies for the central nervous system, particularly cannabinoid-based pharmaceuticals. They have established a diverse pipeline focused on meeting urgent medical needs, including SCI-110 for Tourette Syndrome and SCI-210 for conditions such as autism spectrum disorders and status epilepticus. Additionally, SciSparc holds a substantial stake in a subsidiary that sells hemp oil-based products via established online platforms.
Frequently Asked Questions
1. What is the primary goal of the Phase IIb clinical trial?
The main objective is to assess the efficacy, safety, and tolerability of SCI-110 for treating Tourette Syndrome in adults.
2. Where will the clinical trial be conducted?
The trial will take place at prominent institutions like Yale School of Medicine, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
3. What does SCI-110 target?
SCI-110 is specifically designed to treat Tourette Syndrome with the aim of reducing tic severity.
4. How will participants be selected for the trial?
Participants aged 18 to 65 who have been diagnosed with Tourette Syndrome will be randomly assigned to receive either SCI-110 or a placebo.
5. What is the significance of this trial for patients?
A successful outcome could lead to more effective treatments for those suffering from Tourette Syndrome, ultimately enhancing their quality of life.
